Cowen & Co. Gives a Hold Rating to Regeneron

By Jason Carr

Cowen & Co. analyst Phil Nadeau assigned a Hold rating to Regeneron (NASDAQ: REGN) yesterday and set a price target of $450. The company’s shares opened today at $393.62.

According to, Nadeau is a 5-star analyst with an average return of 11.8% and a 51.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Regeneron is Moderate Buy and the average price target is $486, representing a 23.5% upside.

In a report issued on November 3, Robert W. Baird also upgraded the stock to Hold with a $408 price target.

Based on Regeneron’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.5 billion and quarterly net profit of $388 million. In comparison, last year the company earned revenue of $1.22 billion and had a net profit of $265 million.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in inventing medicines for people with serious diseases. It includes Arcalyst, Dupixent, Eylea, Kevzara, and Praluent injections. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.